ENTSTAR 001
Alternative Names: ENTSTA 001; ENTSTAR001Latest Information Update: 10 Sep 2024
At a glance
- Originator Entos Pharmaceuticals
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action ATP binding cassette transporter subfamily A member 4 replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Stargardt disease
Highest Development Phases
- Research Stargardt disease
Most Recent Events
- 30 Aug 2024 ENTSTAR 001 is available for licensing as of 30 Aug 2024. https://entospharma.com/pipeline-%26-partners#11ffd71c-cc8d-4768-bdb3-302fe5cac551
- 30 Aug 2024 Early research in Stargardt disease in Canada (Ophthalmic), prior to August 2024 (Entos Pharmaceuticals pipeline, August 2024)